Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Microbix Biosystems Inc T.MBX

Alternate Symbol(s):  MBXBF

Microbix Biosystems Inc. develops and commercializes biological and technological solutions for human health and wellbeing. It enables the commercialization of diagnostic assays by making a range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its segments include development, manufacturing and sales of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples and, and development and commercialization of novel and proprietary products or technologies, such as Kinlytic. Its Kinlytic urokinase is a biologic thrombolytic drug used to treat blood clots.


TSX:MBX - Post by User

Comment by Mbxwatcheron Jul 26, 2023 9:12am
140 Views
Post# 35557387

RE:RE:New Press Release - Microbix Presents Results of STI Test Controls at AACC

RE:RE:New Press Release - Microbix Presents Results of STI Test Controls at AACCHonestly, these kinds of announcements go completely unnoticed.

We are down .06-.07 since they made the Kinlytic announcement which (and I agree with Wiz,) is ultimately transformational for Microbix.

IMO the financial performance of the company is underwhelming for this fiscal year.
It is a microcap and is being punished accordingly.......If we believe in the story, and I still do, this is a buying opportunity for those who can...and a Hold for those who can.

The absence of any VTM for this fiscal year has/will put a sizeable dent in this years performance, possibly offset somewhat by the payments made on the Kinlytic deal.

Until then we wait for more QAPS deals, incremental improvement in Antigens, and a little further down the road, the rebirth of Kinlytic.   My guess based on the share price is there are those who no longer choose to wait.
<< Previous
Bullboard Posts
Next >>

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse